MedPath

Acrux Receives FDA Approval for Nitroglycerin Ointment and Secures $2.65 Million Funding

• Acrux Limited has gained FDA approval for its Nitroglycerin Ointment, marking a significant milestone for the company's product portfolio. • The company has also secured $2.65 million through a share placement with institutional investors to bolster its market expansion efforts. • A share purchase plan for eligible shareholders complements the funding round, further supporting Acrux's strategic initiatives in the pharmaceutical sector.

Acrux Limited has announced the FDA approval of its Nitroglycerin Ointment, accompanied by $2.65 million in funding secured through a share placement to institutional investors. This dual achievement underscores Acrux's strategic focus on expanding its presence in the pharmaceutical market.
The funding, coupled with a share purchase plan for eligible shareholders, is intended to support the commercialization and further development of Acrux's product pipeline. The FDA approval of the Nitroglycerin Ointment represents a key regulatory milestone for the company, paving the way for its introduction to the U.S. market.
Acrux intends to leverage this recent approval and financial injection to strengthen its market position and pursue additional opportunities within the pharmaceutical landscape. The company's strategic initiatives are designed to drive growth and enhance shareholder value through targeted investments and product development efforts.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Axcynsis Therapeutics' AT03-65, a CLDN6-Targeting ADC, Receives FDA IND Clearance

Axcynsis Therapeutics received FDA clearance for its IND application for AT03-65, an ADC targeting CLDN6-positive solid tumors, marking a key regulatory milestone.
AT03-65 utilizes AxcynDOT™, Axcynsis' proprietary payload with a novel mechanism, representing the first program using this technology to enter clinical trials.

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).
Crinecerfont is designed to reduce elevated androgen levels in individuals with CAH, addressing a critical unmet need in current treatment.

Lupin Gains FDA Approval for Generic Adderall XR for ADHD Treatment

Lupin has received FDA approval for its generic version of Adderall XR, an extended-release capsule used to treat ADHD in adults and children.
The approved Abbreviated New Drug Application (ANDA) includes multiple dosage strengths, ranging from 5 mg to 30 mg.

Shandong Xinhua Pharma Gains Approval for Febuxostat Tablets in China

Shandong Xinhua Pharmaceutical's subsidiary, Shandong Zibo Xincat Pharmaceutical, has received approval from China's National Medical Products Administration for its febuxostat tablets.
The approval allows the company to manufacture and sell febuxostat tablets, potentially enhancing its market position within the Chinese pharmaceutical industry.

Shandong Xinhua Pharmaceutical Receives Approval for Generic Cefuroxime Axetil Dispersible Tablets in China

Xincat Pharmaceutical, a subsidiary of Shandong Xinhua Pharmaceutical, has received approval from China’s National Medical Products Administration for its cefuroxime axetil dispersible tablets.
The approval confirms the quality and efficacy of Xincat Pharmaceutical's cefuroxime axetil dispersible tablets as a generic drug, expanding the company's market presence.

Scilex Pharmaceuticals Achieves FDA Agreement on NDA Path for SP-103 in Chronic Neck Pain

Scilex Pharmaceuticals secured FDA agreement on the NDA path for SP-103, a lidocaine topical system 5.4%, following a successful end-of-Phase II meeting.
SP-103, a next-generation, triple-strength formulation of ZTlido, targets chronic neck pain associated with muscle spasms, a market projected to reach $134.5 billion.

Shuttle Pharmaceuticals' Ropidoxuridine Shows Promise in Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma.
The trial is evaluating ropidoxuridine as a radiation sensitizer to enhance the effectiveness of radiation therapy.

Acrivon Therapeutics Grants Equity Awards to Employees Under Nasdaq Rule 5635(c)(4)

Acrivon Therapeutics has granted equity awards to employees under its 2023 Inducement Plan, consisting of options to purchase 61,950 shares of common stock.
The stock options vest over time, contingent upon continued employment, with 25% vesting after one year and the remainder in monthly installments.

FDA Approves Incyte and Syndax's Niktimvo for Chronic Graft-versus-Host Disease

The FDA has approved Niktimvo, developed by Incyte and Syndax Pharmaceuticals, for treating chronic graft-versus-host disease (cGVHD).
Niktimvo is intended for adult and pediatric patients (weighing at least 88.2 pounds) who have failed at least two prior systemic therapies.

FDA Expands Furoscix Indication to Include NYHA Class IV Heart Failure Patients

The FDA has approved scPharmaceuticals' supplemental New Drug Application (sNDA) for Furoscix, expanding its indication to include NYHA Class IV chronic heart failure patients.
This expansion allows Furoscix to be used in the most symptomatic heart failure patients, who experience the greatest limitations on physical activity, representing approximately 10% of all heart failure patients.

Reference News

[1]
Acrux Gains FDA Approval and Raises $2.65 Million | Markets Insider
markets.businessinsider.com · Dec 5, 2024

Acrux Limited announced U.S. FDA approval of Nitroglycerin Ointment and secured $2.65 million via a share placement, hig...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy